AARD Aardvark Therapeutics, Inc.
$1.51▲ +16.15%
Healthcare
Other
After hours
$1.43▼ -5.30%
Oct 28, 6:35 PM ET
Volume 2.02M
Avg Volume (10D) 2.77M
Key Metrics & Fundamentals
Market Cap
$33.05M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.93 - 16.60
% vs 50 MA
-69.62%
% vs 200 MA
-76.62%
RSI-14
25.7
MACD Histogram
-0.2900
Beta (1Y vs SPY)
3.81
Free Cash Flow
-$17.60M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$15.08M
COGS
–
Operating Exp
$15.08M
Operating Income
-$15.08M
EBIT
-$15.08M
Pretax Income
-$14.39M
Net Income
-$14.39M
EPS (Diluted)
-0.66
Price & Volume History
Loading chart…
Recent News
HC Wainwright Adjusts PT on Aardvark Therapeutics to $2 From $4, Maintains Neutral Rating
MT Newswires · Oct 26, 2026 6:35 AM ET
Sector Update: Healthcare Stocks Fall Late Afternoon
MT Newswires · Oct 23, 2026 3:56 PM ET
Top Midday Decliners
MT Newswires · Oct 23, 2026 2:30 PM ET
Top Premarket Decliners
MT Newswires · Oct 23, 2026 7:43 AM ET
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
GlobeNewswire · Oct 23, 2026 7:00 AM ET
Aardvark Therapeutics stock surges as FDA lifts clinical hold
Investing.com · Oct 22, 2026 5:57 PM ET
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
GlobeNewswire · Oct 22, 2026 4:05 PM ET
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
Zacks · Oct 21, 2026 11:00 AM ET
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
PR Newswire · Oct 12, 2026 10:31 AM ET
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
GlobeNewswire · Oct 8, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See AARD's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.